K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?

Springer Science and Business Media LLC - Tập 38 - Trang 739-743 - 2006
Mingxin Wei1,2, Hulya Taskapan1,3, Khaled Esbaei1,4, Sarbjit Vanita Jassal1, Joanne M. Bargman1, Dimitrios G. Oreopoulos1
1Home Peritoneal Dialysis Unit, University Health Network and University of Toronto, Toronto, Canada
2Department of Nephrology, Guangxi People’s Hospital, Nanning City, P.R. China
3Department of Nephrology, Inonu University Medical Faculty, Malatya, Turkey
4Tripoli Central Hospital, Al-Fatah University, Tripoli, Libya

Tóm tắt

Background: Mineral metabolism has emerged as an important predictor of morbidity and mortality in dialysis patients. Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines for bone metabolism and disease in chronic kidney disease (CKD) recommend that, in Stage 5 CKD, the target levels for calcium (Ca) (corrected for serum albumin), phosphate (P), calcium × phosphate (Ca × P) product and parathyroid hormone (PTH) levels should be maintained at 8.4–9.5 mg/dl, 3.5–5.5 mg/dl, < 55 mg2/dl2 and 150–300 pg/ml, respectively. Objectives: To evaluate our ability to achieve K/DOQI guidelines for bone metabolism and disease targets in our patients and to compare them between patients on hemodialysis (HD) and peritoneal dialysis (PD) and also with those reported in the literature. Methods: We reviewed bone metabolism laboratory parameters in 57 HD patients and 69 PD patients, who had been on dialysis for more than 9 months. Results: The percentage of patients whose serum Ca, P, Ca × P product and PTH were within K/DOQI recommended target ranges were 46%, 53%, 77% and 28% in HD patients and 52%, 65%, 77% and 23% in PD patients, respectively. There were no significant differences between HD and PD patients in the percentage of all parameters that were within K/DOQI recommended target ranges. The percentage of our HD patients who had Ca, P, and PTH levels within recommended target range was similar to those in previous reports. Conclusion: In our unit, the management of bone and mineral metabolism in HD and PD patients is still far short of meeting K/DOQI guidelines. These findings appear similar in HD and PD patients. Our findings resemble those reported in the literature.

Tài liệu tham khảo

Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31(4):607–617

Hsu CH (1997) Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 29(4):641–649

Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, et al. (2004) Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44(5 Suppl 3):34–38

Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, et al. (2005) Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67(3):1179–1187

Eknoyan G, Levin A, Levin NW (2003) Bone metabolism and disease in chronic kidney disease. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease Am J Kidney Dis 42(4):S1–S201

Block GA (2000) Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol 54(4):318–324

Levin NW, Hoenich NA (2001) Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients. Curr Opin Nephrol Hypertens 10(5):563–568

Cannata-Andia JB, Rodriguez-Garcia M (2002) Hyperphosphataemia as a cardiovascular risk factor—how to manage the problem. Nephrol Dial Transplant 17(Suppl 11):16–19

Stompor TP, Pasowicz M, Sulowicz W, Dembinska-Kiec A, Janda K, Wojcik K, et al. (2004) Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis. Am J Kidney Dis 44(3):517–528

Malluche HH, Monier-Faugere MC (1992) Risk of adynamic bone disease in dialyzed patients. Kidney Int 38(Suppl):S62–S67

Malluche HH, Faugere MC (1988) Aluminum-related bone disease. Blood Purif 6(1):1–15

Alfrey AC, LeGendre GR, Kaehny WD (1976) The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294(4):184–188

Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC (1996) Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients. Am J Kidney Dis 27(3):394–401

Hüting J (1994) Mitral valve calcification as an index of left ventricular dysfunction in patients with end-stage renal disease on peritoneal dialysis. Chest 105(2):383–388

Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342(20):1478–1483

Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, et al. (1998) Cardiac valve calcification in hemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 13(8):2037–2040

Raggi P (2000) Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in hemodialysis patients. Clin Nephrol 54(4):325–333

Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31(4):607–617

Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ et al. (2005) Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 16(8):2501–2508

Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W et al. (2005) Two-year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 20(8):1653–1661

Qunibi WY, Nolan CR (2005) Economic impact of sevelamer in patients with ESRD. Kidney Int 67(4):1636–1637

Abderrhamane G, Renato D, Patrick F (2005) Opportunity and cost of sevelamer in dialysis patients. Kidney Int 67(4):1636

Manns B, Stevens L, Miskulin D, Owen WF Jr, Winkelmayer WC, Tonelli M (2004) A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66(3):1239–1247

Braun J, Asmus HG, Holzer H, Brunkhorst R, Krause R, Schulz W, et al. (2004) Long-term comparison of a calcium-free phosphate binder and calcium carbonate–phosphorus metabolism and cardiovascular calcification. Clin Nephrol 62(2):104–115

Sturtevant JM, Hawley CM, Reiger K, Johnson DW, Campbell SB, Burke JR, et al. (2004) Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. Nephrology (Carlton) 9(6):406–413

Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, et al. (2005) Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 100(1):c8–c19 Epub 2005 Apr 4

Molony DA, Murthy B (2005) Accumulation of metals and minerals from phosphate binders. Blood Purif 23(Suppl 1):2–11

Behets GJ, Verberckmoes SC, Oste L, Bervoets AR, Salome M, Cox AG, et al. (2005) Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 67(5):1830–1836

Al Aly Z, Gonzalez EA, Martin KJ, Gellens ME (2004) Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol 24(4):422–426 Epub 2004 Aug 11

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 38

739-743

Thông tin tác giả